The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities
The investigational subcutaneous hepcidin mimetic peptide is designed to regulate iron and red blood cell production
WCK 5222 is the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorisation
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
The portfolio, purchased from a leading multinational generic manufacturer, addresses a market valued at $473.2 million for the 12 months ending August 2025
The resubmission of BLA for MOLBREEVI names Fujifilm as the drug substance manufacturer
If approved, imlifidase has the potential to transform the kidney transplant landscape by enabling highly sensitized patients to also have access to a potentially life-changing kidney transplant
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments tied to preclinical, development, regulatory, and commercial achievements
Subscribe To Our Newsletter & Stay Updated
